• 22-02-2012 - Appendix 4D - Half Yearly Report and Accounts
• 13-02-2012 - ANP to present at BIO CEO & Investor Conference
• 09-02-2012 - ATL1103 Development Update
• 26-01-2012 - Appendix 4C - Quarterly Cashflow Report
• 23-01-2012 - Appendix 3B
• 05-01-2012 - Change of Registry Services

• 22-12-2011 - Appendix 3B
• 16-12-2011 - ATL1101 for Cancer - Extension of Option to License
• 07-12-2011 - ATL1103 Successfully progresses towards Phase ll Clinical Trial
• 29-11-2011 - Appendix 3B
• 25-11-2011 - Appendix 3B
• 22-11-2011 - Appendix 3B
• 21-11-2011 - Appendix 3B
• 15-11-2011 - Appendix 3B
• 08-11-2011 - 2011 AGM Results
• 08-11-2011 - 2011 AGM Chairman's Address and Presentation
• 07-11-2011 - ATL1103 Japanese Patent Granted
• 11-10-2011 - Dosing Completed in ATL1103 Clinical Trial
• 05-10-2011 - Notice of Annual General Meeting & Annual Report
• 04-10-2011 - Appendix 3Y - Change of Director's Interest Notice
• 30-09-2011 - Appendix 3Y - Change of Director's Interest Notice
• 30-09-2011 - Appendix 3Y- Change of Director's Interest Notice
• 20-09-2011 - ATL1102 New Stem Cell Mobilization Indication
• 14-09-2011 - Dosing commences in Final Stage of Clinical Trial of ATL1103
• 16-08-2011 - ATL1103 Clinical Development Presentation
• 11-08-2011 - Appendix 4E
• 12-07-2011 - ATL1101 New Patents
• 05-07-2011 - ATL1101 for Cancer - Exclusive Option to License
• 30-06-2011 - Appendix 3B
• 29-06-2011 - Dosing commences in Clinical Trial of ATL1103
• 15-06-2011 - Approval to commence Phase I Clinical Trial of ATL1103
• 09-06-2011 - ANP Receives Funding to Complete Additional Key Studies on ATL1103
• 09-06-2011 - Appendix 3B and 708A Notice
• 03-06-2011 - Appendix 3B
• 29-04-2011 - Appendix 3B
• 21-04-2011 - Appendix 4C Quarterly Cashflow Report
• 11-04-2011 - ATL1103 Potential in Cancer Treatment
• 24-03-2011 - Response to ASX Pricy Query
• 21-02-2011 - Final Preparations for ATL1103 Clinical Trial
• 10-01-2011 - ATL1103 Summary Background and Development Update

• 23/12/2010 – Antisense Therapeutics Ltd Trading Policy
• 13/12/2010 – Appendix 3Y – Change of Director’s Interest Notice
• 10/12/2010 – Rights Issue – Allotment of shares
• 08/12/2010 – ATL1103 – Additional US Patent Granted
• 07/12/2010 – Completion of $2.4 Million Rights Issue
• 17/11/2010 – Investor Presentation
• 10/11/2010 – Antisense Rights Offer
• 09/11/2010 – Results of AGM
• 05/11/2010 – Receipt of Research & Development Tax Concession Refund
• 01/11/2010 – Letter to Option holders
• 01/11/2010 – Letters to Shareholders
• 01/11/2010 – Appendix 3B
• 01/11/2010 – Rights Issue Prospectus
• 01/11/2010 – Fully Underwritten Renouncable Rights Issue
• 27/10/2010 – Appendix 4C Quarterly Cashflow Report
• 13/10/2010 – Patent Progress – ATL1103 and Inhaled ATL1102
• 08/10/2010 – Release of Securities from Escrow
• 07/10/2010 – Notice of Annual General Meeting & Annual Report
• 08/09/2010 – ANP to present at Rodman & Renshaw Annual Global Investment Conference
• 26/08/2010 – Appendix 4E Preliminary Final Report
• 10/08/2010 – Appendix 3B
• 21/07/2010 – Resignation of Joint Company Secretary
• 21/07/2010 – Appendix 4c Quarterly Cashflow Report
• 13/07/2010 – Significant Progress on Licensing Opportunities
• 19/05/2010 – ANP to present to Isis Shareholders in the US
• 11/05/2010 – Appendix 3B
• 04/05/2010 – Business Operations Update
• 29/04/2010 – Appendix 4C – Quarterly Cashflow Report
• 21/04/2010 – ATL1101 Prostatce Cancer Data presented at US Scientific Meeting
• 24/03/2010 – ATL1102 License Agreement with Teva Pharmaceutical Industries Ltd
• 17/02/2010 – Appendix 4D Half Yearly Report
• 10/02/2010 – ATL1101 Data Presentation
• 03/02/2010 – ATL1101 Prostate Tumour Suppression Data Published, Patent Granted
• 29/01/2010 – Appendix 4C – Quarterly Cashflow Report

• 24/11/2009 – Allowance of US Patent on ATL1103 & Development Update
• 13/11/2009 – Annual General Meeting Presentation
• 21/10/2009 – Appendix 4C- Quarterly Cashflow Report
• 14/10/2009 – Notice of Initial Substantial Shareholder
• 12/10/2009 – Appendix 3B
• 12/10/2009 – ATL1103 on track to move into development
• 09/10/2009 – Notice of Annual General Meeting & Annual Report
• 09/09/2009 – ANP License Partner to Present at Leading Global MS Congress
• 01/09/2009 – ANP to present at Rodman & Renshaw Healthcare Conference
• 19/08/2009 – Appendix 4E and Annual Financial Report
• 17/08/2009 – New Data on ATL1101 Activity in Tumour Cells
• 10/08/2009 – Israeli Tax Position on licensing income received
• 29/07/2009 – Appendix 4C – Quarterly Cashflow Report
• 26/06/2009 – ANP completes ATL/TV1102 Phase IIa Clinical Study Report
• 18/06/2009 – ATL1101 enhances chemotherapy anti-tumour effect
• 01/06/2009 – ANP to Present to Isis Shareholders in US
• 22/05/2009 – Appendix 3Y – Change of Directors Interest Notice
• 21/05/2009 – Market Update
• 30/04/2009 – ATL/TV1102 Phase IIa clinical data presented at the American Academy of Neurology Annual Meeting
• 16/04/2009 – Appendis 4C – Quarterly Cashflow Report
• 09/04/2009 – Change of Directors’ Interest Notice
• 07/04/2009 – Investment Overview Presentation
• 03/04/2009 – Change of Director’s Interest Notice
• 05/03/2009 – Appendix 3Y – Change in Directors Interest Notice
• 16/02/2009 – ATL/TV1102 Clinical Trial Data presented at Keystone Symposia
• 12/02/2009 – Antisense Therapeutics Projects Update
• 05/02/2009 – Appendix 4D – Half Yearly Report
• 29/01/2009 – Appendix 4C – Quarterly Cashflow Report
• 28/01/2009 – Appendix 3Y – Change of Director’s Interest Notice

• 17/12/2008 – ATL1103 Development on Schedule
• 09/12/2008 – New Appointment to support the ATL/TV1102 Licensing Program
• 19/11/2008 – ATL1101 intellectual property portfolio strengthened
• 06/11/2008 – Change of Director’s Interest Notice
• 05/11/2008 – Change of Director’s Interest Notice
• 31/10/2008 – Annual General Meeting Results
• 31/10/2008 – Annual General Meeting Presentation
• 28/10/2008 – ANP To Present at Rodmand & Renshaw Healthcare Conference
• 17/10/2008 – ATL1101 Preclinical Data in Prostate Cancer-US Presentation
• 15/10/2008 – ATL1101 suppresses tumours in prostate cancer animal study
• 14/10/2008 – Appendix 4C – Quarterly Cashflow Report
• 24/09/2008 – Notice of AGM
• 22/09/2008 – ANP and Isis Investor Conference Call Webcast
• 16/09/2008 – Teva Pharmaceuticals Announcement re MS World Congress
• 10/09/2008 – Investor Presentation
• 28/08/2008 – ATL/TV1102 data to be presented at MS Scientific Meeting
• 26/08/2008 – Results of General Meeting
• 13/08/2008 – Preliminary Final Report – Appendix 4E
• 05/08/2008 – Market Update
• 31/07/2008 – Key Journal highlights IGF-1R as high interest cancer target
• 23/07/2008 – Market Update
• 22/07/2008 – Notice of Meeting Clarification
• 22/07/2008 – Notice of Meeting
• 21/07/2008 – Business and Strategy Update
• 30/06/2008 – Phase IIa MS Trial Success – Teva to continue development
• 02/06/2008 – ANP to present to Isis Shareholders in the US

06/05/2008
17/04/2008

• 18/04/2008 – Notice under Section 708A(5)(e)
• 16/04/2008 – Placement
• 08/04/2008 – Appendix 4C – Quarterly Cashflow Report
• 01/04/2008 – ATL1102 Phase IIa MS Trial Update
• 26/03/2008 – Research Director Receives 2008 Advancing BioBusiness Award
• 17/03/2008 – Final Director’s Interest Notice
• 06/03/2008 – Resignation of Non-Excecutive Director
• 22/02/2008 – ANP to Present at US Investor Conference
• 11/02/2008 – ATL1102 Licensed to Teva Pharmaceutical Industries Ltd
• 07/02/2008 – Market Update – MS Drug Tysabri Sales
• 05/02/2008 – Appendix 4D Half Yearly Report Dec 2007
• 23/01/2008 – Appendix 4C – Quarterly Cash Flow report
• 08/01/2008 – Market Update

• 21/12/2007 – ATL1102 Phase IIa MS Trial Update
• 17/12/2007 – ANP Updated Company Profile
• 29/11/2007 – Change of Constitution
• 21/11/2007 – Results of Annual General Meeting
• 21/11/2007 – ATL1102 Phase IIa Trial Update
• 08/11/2007 – ATL1101 enters Pre-clinical Research in Prostate Cancer
• 29/10/2007 – Joint Company Secretary Announcement
• 26/10/2007 – Appendix 4C – Quarterly Cashflow Report
• 24/10/2007 – Presentation at US Investor Conference
• 18/10/2007 – Notice of Annual General Meeting
• 12/09/2007 – ATL1102 MS Phase IIa Trial Update
• 31/08/2007 – ATL1103 Project Update – Scientific Publication
• 10/08/2007 – Letter to Shareholders
• 03/08/2007 – Preliminary Final Report – Appendix 4E
• 24/07/2007- Appendix 4C Quarterly Cashflow Report
• 22/06/2007 – ATL1102 Phase IIa Multiple Sclerosis Trial Update
• 08/05/2007 – CEO Interview with Aegis Equities Research
• 03/05/2007 – Company Presentation
• 20/04/2007 – Appendix 4C – Quarterly Cashflow Report
• 13/04/2007 – ATL1102 Phase IIa MS Trial Update
• 28/03/2007 – Results of General Meeting
• 27/03/2007 – Further Validation for 2nd Generation Antisense Drugs
• 19/02/2007- Notice of General Meeting
• 07/02/2007 – ATL1102 – European Patent Granted
• 05/02/2007 – Antisense/Isis Extend Development Collaboration
• 30/01/2007 – Appendix 4D – Half Year Report
• 25/01/2007 – Phase IIa Multiple Sclerosis Trial Update
• 24/01/2007 – Appendix 4C – 2nd Quarter Report
• 16/01/2007 – Option Exiry

• 20/12/2006 – ATL1103 to progress towards clinical development
• 15/11/2006 – Appendix 3B
• 15/11/2006 – Section 708A(5)(e)
• 13/11/2006 – Market Developments – Antisense Technology
• 13/11/2006 – Appendix 3B
• 13/11/2006 – Share Placement to Overseas Institutional Investors
• 13/11/2006 – Section 708A(5)(e) Notice
• 03/11/2006 – Change of Director’s Interest Notice
• 24/10/2006 – Appendix 4C Quarterly Cashflow Report
• 17/10/2006 – Chairman’s Address & Presentation
• 11/10/2006 – Animal study results provide further support for the potential of ATL1102 for Multiple Sclerosis
• 10/10/2006 – Annual General Meeting Results
• 04/10/2006 – ATL1102 Phase IIa MS Trial update
• 03/10/2006 – Seminar by Dr Frank Bennett at Bio21 Institute
• 08/09/2006 – Notice of AGM & Annual Report
• 29/08/2006 – Lead Compound ATL1102 – Patent granted in Japan
• 07/08/2006 – Preliminary Final Report – Appendix 4E
• 03/08/2006 – Appendix 3Z – Final Director’s Interest Notice
• 03/08/2006 – Appendix 3X – Initial Director’s Interest Notice
• 25/07/2006 – Appendix 4C – Quarterly Cashflow Report
• 07/07/2006 – Retirement & Appointment of Non-Executive Directors
• 30/06/2006 – Market Developments – Tysabri receives approval in European Union for the treatment of relapsing remitting forms of MS
• 28/06/2006 – Audio Broadcast
• 21/06/2006 – Commencement of dosing of patients in Phase IIa MS Trial
• 20/06/2006 – Appointment of New Company Secretary
• 07/06/2006 – Market Developments – FDA approves reintroduction of Tysabri®
• 28/04/2006 – Market Developments-Validation for 2nd Generation Antisense Drug Devlopment
• 19/04/2006 – Appendix 4C – Quarterly Cashflow report
• 10/04/2006 – Appendix 3B – New Share Issue
• 10/04/2006 – Notice under sec 708A(5)(e) of the Corporations Act 2001
• 06/04/2006 – Results of Extraordinary General Meeting
• 04/04/2006 – Company Update
• 09/03/2006 – Market Developments
• 03/03/2006 – Notice of General Meeting
• 17/02/2006 – Share Placement to Institutional & Professional Investors
• 17/02/2006 – Half Year Report
• 19/01/2006 – Appendix 4C – Quarterly Cashflow Report
• 12/01/2006 – Approval to restart Phase IIa trial in MS patients

• 09/11/2005 – CEO presenting at US Healthcare Conference

• 03/11/2005 – Appendix 3B – Exercise of Options

• 20/10/2005 – Annual General Meeting Results

• 19/10/2005 – Chairman’s Address & Managing Director’s Presentation

• 14/10/2005 – Appendix 4C – Quarterly Cashflow Report

• 04/10/2005 – Results of Proof of Concept study in psoriasis patients

• 14/09/2005 – Annual Report and Notice of AGM

• 12/09/2005 – Animal Data Supports Therapeutic Potential of ATL1103 in eye diseases

• 31/08/2005 – ATL to submit application to restart ATL1102 Phase IIa trial in MS patients

• 12/08/2005 – Preliminary Final Report – Appendix 4E

• 11/08/2005 – Response to Share Price Query

• 21/07/2005 – Appendix 4C – Quarterly Cashflow Report

• 07/07/2005 – Change of Directors Interest

• 07/07/2005 – Appendix 3B – Issue of Employee Options

• 27/06/2005 – Results of General Meeting

• 25/05/2005 – Notice of General Meeting

• 23/05/2005 – Asthma data presented at American Thoracic Society Meeting

• 18/05/2005 – Investor Update

• 19/04/2005 – Appendix 4C – Quarterly Cashflow Report

• 21/03/2005 – Asthma Data to be Presented at Respiratory Medicines Conference

• 10/03/2005 – Antisense Therapeutics Halts ATL1102 Phase 2a MS Trial

• 01/03/2005 – Market Update

• 25/02/2005 – Antisense Inhibition of VLA-4 in mouse model of MS published

• 22/02/2005 – Appendix 3b – Exercise of Options

• 18/02/2005 – Antisense Therapeutics – US Presentations

• 17/02/2005 – Half Year Report

• 02/02/2005 – Investor Update

• 20/01/2005 – Appendix 4C – Quarterly Cashflow Report

• 13/01/2005 – Antisense Therapeutics Establishes Level 1 US ADR Program

• 21/12/2004 – Initiation of Phase IIa Trial of Antisense Drug for MS
• 20/12/2004 – Animal Study Results Point to ATL1102′s Potential For Asthma
• 15/12/2004 – Appendix 3B – Exercise of Options
• 26/11/2004 – Market Developments – New Treatment for MS
• 23/11/2004 – Presentation – Institutional Life Science Forum in London
• 17/11/2004 – ATL1101 for Psoriasis – Approval for “Proof of Concept” Trial
• 27/10/2004 – Appendix 4C – Quarterly Cash Flow Report
• 27/10/2004 – Appendix 3B – Exercise of Options
• 21/10/2004 – ATL to present at Rodman & Renshaw 6th Annual Healthcare Conference
• 20/10/2004 – Annual General Meeting 2004 – Presentation
• 20/10/2004 – Annual General Meeting Results
• 06/10/2004 – Antisense Therapeutics to establish Level 1 ADR Program
• 27/09/2004 – Psoriasis Proof of Concept Study – Update
• 21/09/2004 – Annual Report/Notice of AGM
• 27/08/2004 – Appendix 3B – Exercise of Options
• 26/08/2004 – 2004 Financial Accounts – Appendix 4E
• 30/07/2004 – Appendix 4C – Fourth Quarter Cash Flow Report
• 28/07/2004 – Further Market Developments re Treatment for MS
• 20/07/2004 – New Laboratory at Murdoch Childrens Research Institute
• 09/07/2004 – Appendix 3b – Exercise of Options
• 01/07/2004 – Investor Update – Market Developments re Treatment for MS
• 23/06/2004 – Appendix 3Y – Change of Director’s Interest
• 08/06/2004 – Positive Results from Phase I Trial of ATL1102 for MS
• 07/06/2004 – Presentation – BIO2004 Annual International Convention
• 02/06/2004 – Appendix 3b – Exercise of Options
• 29/04/2004 – Appendix 4c – Third Quarter Cash Flow Report
• 20/04/2004 – ATL1103 Animal Study Results to be presented at International Symposium
• 08/04/2004 – Appendix 3b – Exercise of Options
• 16/03/2004 – Updated Corporate Presentation
• 12/03/2004 – Investor Update March 2004
• 24/02/2004 – Potential New Treatment for Growth & Sight Disorders
• 12/02/2004 – Half Year Report
• 30/01/2004 – Preliminary Phase I results – Neurosciences Conference Presentation
• 30/01/2004 – Appendix 4C – Quarterly Cash Flow Report
• 14/01/2004 – CEO Featured Guest on Biotech Today (US) Radio Program

• 24/12/2003 – Change of Director’s Interest Notice
• 22/12/2003 – Appendix 3B – End of Restriction Period
• 16/12/2003 – Updated Corporate Presentation
• 09/12/2003 – Investor Update
• 05/12/2003 – Securities to be Released from Escrow
• 07/11/2003 – Appendix 3B Issue of shares approved at 2003 AGM
• 31/10/2003 – Results of Annual General Meeting
• 31/10/2003 – AGM Presentation
• 20/10/2003 – Appendix 4C – First Quarter Report
• 20/10/2003 – Cash Reserves of $15.4 million – no borrowings
• 14/10/2003 – Change of Director’s Interest
• 08/10/2003 – Share Purchase Plan Raises $5.4 Million
• 26/09/2003 – 2003 Annual Report and Notice of Annual General Meeting
• 22/09/2003 – Appendix 3B – Exercise of Options
• 02/09/2003 – Share Purchase Plan
• 27/08/2003 – Commencement of Phase I Study for MS Drug
• 22/08/2003 – 2003 Financial Accounts – App 4E
• 22/08/2003 – Information Notification & Application for Quotation
• 20/08/2003 – Share Placement
• 13/08/2003 – Updated Corporate Presentation
• 31/07/2003 – Appendix 4C – Quarterly Report
• 24/07/2003 – ATL to Initiate “Proof Of Concept” Study for Psoriasis Project
• 17/06/2003 – Presentation – Boston Bio-Relationships Conference
• 05/06/2003 – Antisense Psoriasis Therapy Achieves Important Milestone
• 19/05/2003 – $1.1 Million R&D Start Grant Approved for Psoriasis Project
• 28/04/2003 – Appendix 4C – Quarterly Report
• 28/03/2003 – Company Presentation
• 18/02/2003 – Investor Update
• 07/02/2003 – Half-Yearly Report (Appendix 4B)& Operations Report 31 December 2002
• 04/02/2003 – Approval for Trials to Commence on new MS Treatment
• 31/01/2003 – Appendix 4c Quarterly Report

• 11-12-2002 – Change of Director’s Interest
• 10-12-2002 – Allotment of Shares
• 09-12-2002 – General Meeting: 9 December, 2002
• 28-11-2002 – Share Placement – Closed Oversubscribed
• 22-11-2002 – Application for Quotation of Securities (Appendix 3B)
• 14-11-2002 – Announcement: Share Placement – Early Close
• 06-11-2002 – Shares to be released from escrow
• 06-11-2002 – Appendix 3B – New Issue Announcement
• 01-11-2002 – Share Placement
• 01-11-2002 – Offer Information Statement
• 25-10-2002 – Annual General Meeting – 2002
• 24-10-2002 – Presentation at Annual General Meeting
• 11-10-2002 – Appendix 4C
• 08-10-2002 – Investor Release
• 20-08-2002 – Announcement